Büchler M, Friess H
Department of General Surgery, University of Ulm, Germany.
Digestion. 1993;54 Suppl 1:41-6. doi: 10.1159/000201076.
Major pancreatic resection is still accompanied by considerable morbidity and even mortality. Complications which occur after pancreatic surgery are chiefly associated with exocrine pancreatic secretion, hence, the inhibition of exocrine pancreatic secretion perioperatively is a promising concept in the prevention of complications. The hormone somatostatin and its synthetic analogue octreotide have been shown to profoundly inhibit exocrine pancreatic secretion, particularly the secretion of proteases. In a randomized, placebo-controlled, multicenter double-blind trial we analyzed the potential role of octreotide in the prevention of postoperative complications after major pancreatic surgery. A significant reduction in complications such as fistula, abscess, fluid collection, sepsis, pulmonary insufficiency, and postoperative acute pancreatitis could be demonstrated in patients who received octreotide at 3 x 100 micrograms/day subcutaneously. Octreotide was particularly effective in patients undergoing Whipple resection for cancer.
胰脏大切除术仍伴随着相当高的发病率甚至死亡率。胰腺手术后出现的并发症主要与胰腺外分泌有关,因此,围手术期抑制胰腺外分泌是预防并发症的一个有前景的概念。激素生长抑素及其合成类似物奥曲肽已被证明能显著抑制胰腺外分泌,尤其是蛋白酶的分泌。在一项随机、安慰剂对照、多中心双盲试验中,我们分析了奥曲肽在预防胰脏大手术后并发症方面的潜在作用。皮下注射3×100微克/天奥曲肽的患者,瘘、脓肿、积液、败血症、肺功能不全和术后急性胰腺炎等并发症显著减少。奥曲肽对因癌症接受惠普尔手术的患者特别有效。